Nanostructure Conjugates for Selective Extrasynaptic NMDA Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NMDA receptor antagonists fail to differentiate between physiological synaptic and pathological extrasynaptic activity, leading to adverse side effects by inhibiting normal synaptic signaling.
Innovation Solution
Development of nanostructure conjugates, such as gold nanoparticles linked to NMDA modulators like memantine, with a hydrodynamic diameter larger than synaptic cleft openings, to selectively inhibit extrasynaptic NMDA receptors while preserving synaptic function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional NMDA receptor antagonists are used to block pathological extrasynaptic activity, then neuroprotective effects are achieved, but normal synaptic signaling is also inhibited causing adverse side effects
Solution Approach 1:
The invention segments the NMDA receptor population into two distinct targets: synaptic NMDA receptors (sNMDARs) and extrasynaptic NMDA receptors (eNMDARs). By using nanostructure conjugates with sizes larger than the synaptic cleft (25±5 nm), the antagonist is physically segmented from reaching synaptic receptors while still accessing extrasynaptic receptors. This spatial segmentation allows selective blockade of eNMDARs responsible for pathological activity while preserving sNMDARs mediating normal synaptic transmission.
Solution Approach 2:
The invention applies local quality by creating a size-dependent distribution of the antagonist. The nanostructure conjugate has a specific hydrodynamic diameter (larger than synaptic cleft opening) that determines its local accessibility: it can reach extrasynaptic receptors located outside the synaptic cleft but cannot enter the narrow synaptic cleft to reach synaptic receptors. This local quality difference in accessibility resolves the contradiction by providing location-specific pharmacological action.
2Adaptability or versatility
If the antagonist size is increased to prevent synaptic cleft entry, then selective extrasynaptic inhibition is achieved, but the ability to reach any NMDA receptor is reduced
Solution Approach 1:
The invention transitions from considering only the chemical properties of the antagonist to incorporating the spatial dimension of the synaptic cleft. By designing the antagonist as a nanostructure with a hydrodynamic diameter larger than the synaptic cleft width (25±5 nm), the invention uses dimensional constraints to achieve selectivity. This dimensional approach allows the antagonist to access extrasynaptic receptors while being excluded from synaptic receptors, resolving the contradiction between selectivity and accessibility.
Solution Approach 2:
The nanostructure acts as an intermediary carrier that delivers the NMDA receptor antagonist to extrasynaptic locations. The nanostructure's size serves as a filtering mechanism, allowing it to reach extrasynaptic receptors while being physically blocked from entering synaptic clefts. This intermediary approach enables selective delivery of the antagonist to the desired target population without requiring modification of the antagonist's chemical structure.
Data Source
AI summary
Nanostructure conjugates, methods for their preparation, and methods for their use are described. The nanostructure conjugates are useful in inhibiting, activating, and modulating extrasynaptic receptors and ion channels, and in treating various medical conditions among other attractive uses.